Shopping Cart
Remove All
Your shopping cart is currently empty
Lucatumumab
😃Good
Catalog No. T76729Cas No. 903512-50-5
Alias HCD122, HCD 122, CHIR-12.12
Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.
Lucatumumab
Lucatumumab
😃Good
Catalog No. T76729Alias HCD122, HCD 122, CHIR-12.12Cas No. 903512-50-5
Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $448 | In Stock | In Stock | |
| 10 mg | $728 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,480 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.5% (SDS-PAGE); 98.4% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Lucatumumab (HCD122) is a fully human anti-CD40 monoclonal antibody with antitumor activity that blocks the interaction of CD40L with CD40 and inhibits the CD40/CD40L-mediated signaling pathway for the study of chronic lymphocytic leukemia (CLL) and multiple myeloma. |
| In vitro | Lucatumumab (0.001-10 μg/mL; 4 hours) lysed B-cell chronic lymphocytic leukemia (B-CLL) cells by antibody-dependent cell-mediated cytotoxicity (ADCC) action, achieving a mean maximum lysis rate of 49%. [1] Lucatumumab (0.1-10 μg/mL; 3 days) was able to decrease CD40L-induced signaling and reduce B-CLL cell viability. [1] Lucatumumab (10 μg/mL; 24 hours) is able to inhibit cytokine secretion by B-CLL cells. [1] |
| Synonyms | HCD122, HCD 122, CHIR-12.12 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF5/CD40 |
| Molecular Weight | 146.15 kDa |
| Cas No. | 903512-50-5 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Lucatumumab | purchase Lucatumumab | Lucatumumab cost | order Lucatumumab | Lucatumumab in vitro | Lucatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.